Skip to content
Screener

Beam Therapeutics BEAM Q2 2025 earnings

Reported August 5, 2025 · Before market open

Revenue$8.5MMiss by $3.1M
EPS-$1.00Beat by $0.04
Revenue estimate$11.5M
EPS estimate-$1.04

Next report

Nov 3, 2026 (in 2 months)
Revenue estimate$8.8M
EPS estimate-$1.16

Financials

Q2 2025

Income statement

See full
Revenue$8.5M-28.1%
Operating income-$120.2M-14.5%
Net income-$102.3M-12.3%
EPS (diluted)-$1.00+9.9%

Balance sheet

See full
Cash & equivalents$282.1M-3.6%
Total debt$154.8M-6.3%
Total equity$1.0B+22.6%
Total assets$1.4B+10.3%

Cash flow

See full
Operating cash flow-$76.5M+7.9%
CapEx$3.1M+59.9%
Free cash flow-$79.6M+6.3%

Valuation & ratios

Valuation

as of 06/30/25
See full
Market cap$1.72B-10.6%
Enterprise value$1.6B-11.3%
P/S28.6×+23.1×

Profitability

See full
Operating margin-739.9%—
Net margin-659.7%—
FCF margin-589.9%—

Returns & leverage

See full
Return on equity-41.8%—
Debt / equity0.1×0.0×
Current ratio6.8×+0.9×

FAQ

When did Beam Therapeutics report Q2 2025 earnings?
Beam Therapeutics (BEAM) reported Q2 2025 earnings on August 5, 2025 before market open.
What were Beam Therapeutics's Q2 2025 revenue and EPS?
Beam Therapeutics reported revenue of $8.5M and eps of $-1.00 for Q2 2025.
Did Beam Therapeutics beat estimates in Q2 2025?
Revenue missed the consensus estimate of $11.5M by $3.1M. EPS beat the consensus estimate of $-1.04 by $0.04.
How did Beam Therapeutics's Q2 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 28.1% from $11.8M a year earlier and eps grew 9.9% from $-1.11.
Where can I find Beam Therapeutics's Q2 2025 SEC filings?
You can read the 8-K earnings release (0000950170-25-102389) and the 10-Q periodic report (0000950170-25-102393) directly on SEC EDGAR. The filing index links above go to sec.gov.